Fig. 5

Effect of critical illness, and loss of FGF21 or FGF21 supplementation during critical illness on FGF21 receptor expression in muscle. Relative mRNA expression of Klb, Fgfr1 and Fgfr4 was quantified in gastrocnemius muscle, 30 h and 5 days after CLP, as compared with healthy pair-fed mice. a 30 h time point in the genetic FGF21 inactivation study. n = 15 for each group. b 5 days time point in the genetic FGF21 inactivation study. Healthy control, Fgf21^+/+: n = 21; Healthy control, Fgf21^−/−: n = 24; Critically ill, Fgf21^+/+: n = 19; Critically ill, Fgf21.^−/−: n = 18. c LY2405319 supplementation study. Healthy control, placebo: n = 18; Healthy control, LY2405319: n = 16; Critically ill, placebo: n = 16; Critically ill, LY2405319: n = 18. * p < 0.05, ** p < 0.01, *** p < 0.001 between healthy control and critically ill mice and § p < 0.05, §§ p < 0.01 between mice treated with placebo or with LY2405319